The Future Of RTSM: Insights And Forecasting With RTSM-Expert Ian Davison

By all expert accounts, 2022 is the year that we can begin seeing the societal shift from late-stage pandemic to early-stage endemic as the world learns to live with the short- and long-term effects of COVID-19. Clinical trial operations, specifically as they relate to randomization and trial supply, have undergone one of the biggest transformations during the pandemic. With the industry adopting direct-to-patient trial supply and remote monitoring on a larger scale, it begs the question: what pandemic-era changes are here for the long-haul and which are likely to phase out? 

We sat down with Medrio’s internal RTSM-expert, Ian Davison, to explore the impact of the pandemic on trial operations and what the future of RTSM technology looks like.